264 related articles for article (PubMed ID: 37915905)
1. Immune checkpoint inhibitors and their interaction with proton pump inhibitors-related interstitial nephritis.
Miao J; Herrmann SM
Clin Kidney J; 2023 Nov; 16(11):1834-1844. PubMed ID: 37915905
[TBL] [Abstract][Full Text] [Related]
2. Proton pump inhibitors and adverse kidney outcomes during immune checkpoint blockade: time to sound the alarm?
Tan HZ; Sprangers B
Clin Kidney J; 2023 Nov; 16(11):1709-1713. PubMed ID: 37915924
[TBL] [Abstract][Full Text] [Related]
3. Variable Expression of Programmed Cell Death Protein 1-Ligand 1 in Kidneys Independent of Immune Checkpoint Inhibition.
Hakroush S; Kopp SB; Tampe D; Gersmann AK; Korsten P; Zeisberg M; Tampe B
Front Immunol; 2020; 11():624547. PubMed ID: 33552089
[TBL] [Abstract][Full Text] [Related]
4. Acute Interstitial Nephritis and Checkpoint Inhibitor Therapy: Single Center Experience of Management and Drug Rechallenge.
Manohar S; Ghamrawi R; Chengappa M; Goksu BNB; Kottschade L; Finnes H; Dronca R; Leventakos K; Herrmann J; Herrmann SM
Kidney360; 2020 Jan; 1(1):16-24. PubMed ID: 35372854
[TBL] [Abstract][Full Text] [Related]
5. Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy.
Baker ML; Yamamoto Y; Perazella MA; Dizman N; Shirali AC; Hafez N; Weinstein J; Simonov M; Testani JM; Kluger HM; Cantley LG; Parikh CR; Wilson FP; Moledina DG
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35354588
[TBL] [Abstract][Full Text] [Related]
6. Risk factors associated with immune checkpoint inhibitor-induced acute kidney injury compared with other immune-related adverse events: a case-control study.
Gérard AO; Barbosa S; Parassol N; Andreani M; Merino D; Cremoni M; Laurain A; Pinel S; Bourneau-Martin D; Rocher F; Esnault VLM; Borchiellini D; Sicard A; Drici MD;
Clin Kidney J; 2022 Oct; 15(10):1881-1887. PubMed ID: 36158153
[TBL] [Abstract][Full Text] [Related]
7. Immunological mechanisms underlying clinical phenotypes and noninvasive diagnosis of immune checkpoint inhibitor-induced kidney disease.
Seethapathy H; Mistry K; Sise ME
Immunol Rev; 2023 Sep; 318(1):61-69. PubMed ID: 37482912
[TBL] [Abstract][Full Text] [Related]
8. Proton pump inhibitors and traditional nonsteroidal anti-inflammatory drugs and the risk of acute interstitial nephritis and acute kidney injury.
Leonard CE; Freeman CP; Newcomb CW; Reese PP; Herlim M; Bilker WB; Hennessy S; Strom BL
Pharmacoepidemiol Drug Saf; 2012 Nov; 21(11):1155-72. PubMed ID: 22887960
[TBL] [Abstract][Full Text] [Related]
9. Tertiary lymphoid structure signatures are associated with immune checkpoint inhibitor related acute interstitial nephritis.
Singh S; Long JP; Tchakarov A; Dong Y; Yee C; Lin JS
JCI Insight; 2022 Dec; ():. PubMed ID: 36472921
[TBL] [Abstract][Full Text] [Related]
10. Nephrotoxicity in the Age of Immune Checkpoint Inhibitors: Mechanisms, Diagnosis, and Management.
Moturi K; Sharma H; Hashemi-Sadraei N
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203586
[TBL] [Abstract][Full Text] [Related]
11. Pathologic Predictors of Response to Treatment of Immune Checkpoint Inhibitor-Induced Kidney Injury.
Abudayyeh A; Suo L; Lin H; Mamlouk O; Abdel-Wahab N; Tchakarov A
Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358686
[TBL] [Abstract][Full Text] [Related]
12. Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis.
Abdelrahim M; Mamlouk O; Lin H; Lin J; Page V; Abdel-Wahab N; Swan J; Selamet U; Yee C; Diab A; Suki W; Abudayyeh A
Oncoimmunology; 2021 May; 10(1):1927313. PubMed ID: 34104543
[No Abstract] [Full Text] [Related]
13. 'Prevention is better than cure': warning for comedications in patients receiving immune checkpoint inhibitors to avoid acute kidney injury.
Belliere J; Sprangers B
Clin Kidney J; 2022 Oct; 15(10):1803-1806. PubMed ID: 36158160
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitor related nephrotoxicity: Advances in clinicopathologic features, noninvasive approaches, and therapeutic strategy and rechallenge.
Miao J; Sise ME; Herrmann SM
Front Nephrol; 2022; 2():1017921. PubMed ID: 37674988
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review.
Sise ME; Seethapathy H; Reynolds KL
Oncologist; 2019 Jun; 24(6):735-742. PubMed ID: 30902916
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological Features of Kidney Injury Related to Immune Checkpoint Inhibitors: A Systematic Review.
Xu LY; Zhao HY; Yu XJ; Wang JW; Zheng XZ; Jiang L; Wang SX; Liu G; Yang L
J Clin Med; 2023 Feb; 12(4):. PubMed ID: 36835884
[TBL] [Abstract][Full Text] [Related]
17. All-cause and immune checkpoint inhibitor-associated acute kidney injury in immune checkpoint inhibitor users: a meta-analysis of occurrence rate, risk factors and mortality.
Chen JJ; Lee TH; Kuo G; Yen CL; Lee CC; Chang CH; Tu KH; Chen YC; Fang JT; Hung CC; Yang CW; Chou WC; Chi CC; Tu YK; Yu Yang H
Clin Kidney J; 2024 Jan; 17(1):sfad292. PubMed ID: 38186874
[TBL] [Abstract][Full Text] [Related]
18. Cytokines and Immune Cell Phenotype in Acute Kidney Injury Associated With Immune Checkpoint Inhibitors.
Farooqui N; Zaidi M; Vaughan L; McKee TD; Ahsan E; Pavelko KD; Villasboas JC; Markovic S; Taner T; Leung N; Dong H; Alexander MP; Herrmann SM
Kidney Int Rep; 2023 Mar; 8(3):628-641. PubMed ID: 36938084
[TBL] [Abstract][Full Text] [Related]
19. Incidence and Clinical Features of Immune-Related Acute Kidney Injury in Patients Receiving Programmed Cell Death Ligand-1 Inhibitors.
Seethapathy H; Zhao S; Strohbehn IA; Lee M; Chute DF; Bates H; Molina GE; Zubiri L; Gupta S; Motwani S; Leaf DE; Sullivan RJ; Rahma O; Blumenthal KG; Villani AC; Reynolds KL; Sise ME
Kidney Int Rep; 2020 Oct; 5(10):1700-1705. PubMed ID: 33102962
[TBL] [Abstract][Full Text] [Related]
20. Incidence, predictors and 6-month overall outcome of acute kidney injury in Chinese patients receiving PD-1 inhibitors.
Qin Z; Liu K; Xu X; Li T; Ge Y; Wu B; Xing C; Mao H
Future Oncol; 2022 May; 18(16):1951-1962. PubMed ID: 35232231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
